Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Enzymatica

2.04 SEK

+2.00 %

Less than 1K followers

ENZY

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Enzymatica

2019202020212022202320242025
Revenue61.3111.257.249.050.945.653.9
growth-%81.5 %-48.5 %-14.5 %4.0 %-10.5 %18.3 %
EBITDA-41.7-12.1-45.2-68.2-48.1-52.1-
EBIT-41.7-12.1-45.2-68.2-48.1-52.1-51.4
Profit before taxes-41.9-13.1-45.7-68.8-49.7-53.3-51.8
Net income-41.0-13.2-45.4-68.7-49.7-53.2-51.9
EPS-0.27-0.10-0.29-0.41-0.28-0.28-0.21
Dividend0.000.000.000.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %

Profitability and return on capital

2019202020212022202320242025
EBITDA-%-68.0 %-10.8 %-79.0 %-139.4 %-94.4 %-114.2 %
EBIT-%-68.0 %-10.8 %-79.0 %-139.4 %-94.4 %-114.2 %-95.3 %
ROE-34.4 %-12.4 %-36.3 %-54.4 %-64.9 %-30.2 %-41.8 %
ROI-27.7 %-8.2 %-28.9 %-39.4 %-39.5 %-27.2 %-36.5 %
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.